Truist Securities Maintained Buy On Axogen, $53 Price Target
Truist Securities maintained its Buy rating on Axogen (AXGN) with a price target of $53.00, implying an upside of 26.4% from the Sep 30 close of $41.92. The note highlighted Axogen's strong product portfolio for peripheral nerve regeneration.